Fabrx Limited

Company description

FabRx is the creation of three academics from University College London, who saw the potential of 3D printing technology for making better medicines. Established in 2014, FabRx is a rapidly growing biotech business that is developing printed medicines and drug-loaded medical devices. FabRx can design and develop drug-loaded polymers for fused-filament printing into controlled or modified release tablets and caplets or polymer-drug blends for SLA printing into tablets and medical devices.

FabRx operates a biotechnology business, which develops 3D printing technology for the precision manufacture of medicines and medical devices.

Project impact

abRx is a research-driven company and in addition to our IP portfolio our staff frequently publish papers in International Journals. Our latest papers are listed below. Contact us for reprints (or you can cut and paste the DOI into a search engine) or to talk about the data. Goyanes, A, Robles-Martinez, P, Buanz, ABM, Basit, AW, Gaisford, S (2015). Effect of geometry on drug release from 3D printed tablets. Int. J. Pharm. (DOI: 10.1016/j.ijpharm.2015.04.069) Tyson, AL, Hilton, ST, Andreae, LC (2015). Rapid, simple and inexpensive production of custom 3D printed equipment for large-volume fluorescence microscopy. Int. J. Pharm. (DOI: 10.1016/j.ijpharm.2015.03.042) Goyanes, A, Buanz, ABM, Hatton, GB, Gaisford, S, Basit AW (2015). 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA). Eur. J. Pharm. Biopharm. (DOI: 10.1016/j.ejpb.2014.12.003) Goyanes, A, Buanz, ABM, Basit, AW, Gaisford, S (2014). Fused-filament 3D printing (3DP) for fabrication of tablets. Int. J. Pharm. (DOI: 10.1016/j.ijpharm.2014.09.044)